Loading…
Loading…
WSNAF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WSNAF and 80,000+ other tickers.
See exactly how WSNAF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WSNAF and 80,000+ other tickers.
Wesana Health Holdings Inc. is a life sciences firm dedicated to advancing and providing psychedelic-based therapies, including psilocybin-enhanced psychotherapy, primarily targeting the treatment of traumatic brain injuries (TBI). The company focuses on pioneering scientifically validated compounds and therapeutic strategies. Its mission is to enable patients suffering from trauma-related neurological, psychological, and mental health conditions to achieve recovery. Wesana Health is headquartered in Chicago, Illinois.
Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - January 24, 2025) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTC Pink: WSNAF) (the "Company") is pleased to announce the appointment of Mark Monaghan and Brendan Purdy to its board of directors. Mr. Monaghan has over 32 years of experience as an advisor, founder, and board member of investment banks and merchant banks.
Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - November 28, 2023) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTCQB: WSNAF) (the "Company"), announced the execution of a Confidential Settlement and Release Agreement ("Settlement Agreement") between Wesana Health Clinics Corp. ("Wesana"), a subsidiary of the Company, and APS Innovations LLC. (the "APS") whereas the Parties agree to amend and restate the outstanding promissory note previously issued by APS to Wesana on September 1, 2022 in the original principal amount of US$1,223,989.
Toronto, Ontario--(Newsfile Corp. - Le 11 juillet/July 2023) - The Exchange has determined that Wesana Health Holdings Inc. (the “Issuer”) has not met the continued listing requirements as set out in CSE Policy 2, Appendix A, section 2A.6. Pursuant to Policy 3 section 3.5(2), the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US patent application covering FT-104, its flagship psychedelic drug candidate.
Former Chicago Blackhawks enforcer Daniel Carcillo spent much of his NHL career getting inside the heads of opposing teams, making sure they knew that if they crossed a certain line, things could go sideways. Today, Carcillo is an entrepreneur whose mission is, for all intents and purposes, the opposite of what he did on the ice.